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Background: Nonylphenol (NP), an environmental organic compound, has been demonstrated to enhance
reactive-oxygen species (ROS) synthesis. Chronic exposure to low-dose adenine (AD) has been reported to induce
chronic kidney disease (CKD).
Methods: In this study, we tested the hypothesis that chronic exposure to NP will aggravate AD-induced CKD
through increasing generations of inflammation, ROS, and apoptosis that could be attenuated by rosuvastatin. Fifty
male Wistar rats were equally divided into group 1 (control), group 2 (AD in fodder at a concentration of 0.25%),
group 3 (NP: 2 mg/kg/day), group 4 (combined AD & NP), and group 5 (AD-NP + rosuvastatin: 20 mg/kg/day).
Treatment was continued for 24 weeks for all animals before being sacrificed.
Results: By the end of 24 weeks, serum blood urea nitrogen (BUN) and creatinine levels were increased in
group 4 than in groups 1–3, but significantly reduced in group 5 as compared with group 4 (all p< 0.05).
Histopathology scorings of renal-parenchymal and tubular damages were significantly higher in group 4 than in
groups 1–3, but remarkably lower in group 5 compared with group 4 (all p< 0.01). Both gene and protein levels
of inflammation, oxidative stress, ROS, and cellular apoptosis were remarkably higher in group 4 compared with
groups 1–3, but lowered in group 5 than in group 4 (all p< 0.001). Conversely, both gene and protein levels of
anti-oxidants, anti-inflammation and anti-apoptosis were markedly increased in group 5 compared with group 4
(all p< 0.001).
Conclusion: NP worsened AD-induced CKD that could be reversed by rosuvastatin therapy.Background
Chronic kidney disease (CKD) has become a growing
epidemic that not only puts a substantial burden on glo-
bal healthcare resources [1-5], but is also an important
cause of mortality and disability worldwide [6,7]. The
risk factors of CKD have been extensively investigated in
many previous epidemiologic and clinical observational* Correspondence: han.gung@msa.hinet.net
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reproduction in any medium, provided the orstudies [1,3-5,8-11]. Although age, diabetes mellitus, and
hypertension have been well reported to be the prevalent
CKD risk factors [1,11-13], other risk factors including
genetic, racial or familial predisposition [14,15], “west-
ern” lifestyle [1], infectious diseases with infection-
related glomerulonephritis [16], and chronic exposure to
certain chemicals [17,18], may also play an important
role in the initiation and propagation of CKD. However,
the potential impact of chronic exposure to environmen-
tal contaminants on the initiation and aggregation of
CKD has scarcely been reported.
Nonylphenol (NP), an environmental organic com-
pound derived from alkylphenols, has a chemical struc-
ture mimicking that of natural estrogen in the animal/
human body [19-21]. Since previous studies have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function of endocrine-reproductive systems through
binding to the estrogen receptors [19-23], NP and
other environmental contaminants have been recently
categorized into endocrine-disrupting chemicals [24].
Interestingly, a study using animal model has revealed
that chronic exposure to low-dose of NP can induce
polycystic kidney disease in rats [25]. The underlying
mechanisms, however, has not been fully investigated.
Besides, previously animal model study has shown that
chronic exposure to adenine (AD), an important com-
ponent of DNA, can cause crystal formation in kidney
parenchyma and also CKD [26,27]. Thus, AD-induced
CKD in rats has long been accepted as an experimental
model for investigating the pathologies and mechan-
isms of CKD [26-28].
Although inflammatory reaction, oxidative stress, and
the generation of reactive oxygen species (ROS) have
been reported to be the principal mechanisms involved
in various etiologies of CKD [1,17,18,29-32], whether
similar contributors are also responsible for environ-
mental organic compound-induced CKD remains un-
clear. Beside its action in lowering the serum
cholesterol, Rosuvastatin has also been reported to pos-
sess anti-inflammatory and anti-oxidant properties [33].
Accordingly, this study tested the hypothesis that
chronic exposure to NP will aggravate AD-induced
CKD in a rat model that could be attenuated by rosu-




All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at
our hospital and performed in accordance with the
Guide for the Care and Use of Laboratory Animals
(NIH publication No. 85–23, National Academy Press,
Washington, DC, USA, revised 1996). All the techni-
cians who performed the bench work blinded in the
treatment protocol.
Animal model and blood sampling for levels of serum
creatinine and blood urea nitrogen after CKD induction
Fifty pathogen-free, 8-week-old male Wistar rats, weigh-
ing about 250 g (Charles River Technology, BioLASCO
Taiwan Co., Ltd., Taiwan) were equally divided into
group 1 (control), group 2 [AD in fodder at a concentra-
tion of 0.25% (i.e. 1 gm of AD in 100 gm of chow)],
group 3 [NP (2.0 mg/kg/day) by gavage], group 4 (com-
bined AD+NP), and group 5 [combined AD+NP+
rosuvastatin (20 mg/kg/day) by gavage]. The dosage of
rosuvastatin for the animals was based on our previous
study [34] and the dosage of AD for the animals wasaccording to previous reports [27-29] with some modifi-
cations. The AD was administered in fodder rather than
by gavage due to the pharmacokinetic half life of AD
was rather shorter.
AD, NP, and rosuvastatin were given to the animals
for totally 24 weeks. The body weight, concentrations
of serum creatinine and blood urea nitrogen (BUN)
were measured every four weeks during the course of
the experiment.
Blood sampling, collection of 24-hour urine for renal
function assessment and collection of kidney tissue
By the end of 24 weeks of treatment, the animals were
sacrificed. The kidneys were collected for individual
study, while the blood samples were collected for serum
levels of BUN and creatinine. Quantification of BUN
and creatinine level was performed using standard la-
boratory equipment at our hospital. For further deter-
mining the renal function, the ratio of protein to
creatinine which was also utilized was based on our re-
cent report [35].
Hematoxylin and eosin staining, histopathology scoring
and Periodic Acid-Schiff (PAS) staining
Kidney specimens from all animals were fixed in 10%
buffered formalin before embedding in paraffin. Tissue
was sectioned at 5 μm before being stained with
hematoxylin and eosin (H & E) for light microscopic
analysis. Histopathology scoring was applied as
described previously [36] in a blind fashion. The score
was given based on grading of tubular necrosis, loss of
brush border, cast formation, and tubular dilatation in
10 randomly chosen, non-overlapping fields (200x) as
follows: 0 (none), 1 (≤10%), 2 (11–25%), 3 (26–45%), 4
(46–75%), and 5 (≥76%).
Additionally, to determine the architecture of base-
ment membrane and the structure of renal tubular
border, Periodic Acid Schiff (PAS) staining was utilized
in the present study.
Immunofluorescence (IF) and Immunohistochemical (IHC)
studies
IF staining was performed for the examinations of CD68
(macrophage surface marker)-positive cells using re-
spective primary antibodies. Additionally, IHC labeling
technique was adopted for identifying glutathione reduc-
tase (GR)-positive cells using respective primary anti-
body. Irrelevant antibodies were used as controls in the
current study.
Western Blot Analyses for Nuclear Factor (NF)-κB,
Intercellular Adhesion Molecule (ICAM)-1, Heme Oxy-
genase (HO)-1, NAD(P)H Quinone Oxidoreductase
(NQO) 1, NADPH oxidase (NOX)-1 and NOX-2 in
Kidney.
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were loaded and separated by SDS-PAGE using 8–10%
acrylamide gradients. Following electrophoresis, the
separated proteins were transferred electrophoretically
to a polyvinylidene difluoride (PVDF) membrane (Amer-
sham Biosciences). Nonspecific proteins were blocked by
incubating the membrane in blocking buffer (5% nonfat
dry milk in T-TBS containing 0.05% Tween 20) over-
night. The membranes were incubated with the indi-
cated primary antibodies (NQO- 1, 1: 1000, Abcam;
GPx, 1: 2000, Abcam; HO-1, 1: 250, Abcam; ICAM-1, 1:
2000, Abcam; NF-κB, 1: 200, Santa Cruz; Actin 1: 10000,
Chemicon; NOX-1, 1:1500, Sigma; NOX-2, 1:500, Sigma)
for 1 hour at room temperature. Horseradish
peroxidase-conjugated anti-rabbit immunoglobulin IgG
(1: 2000, Cell signaling) was used as a second antibody
for 1 hour at room temperature. The washing procedure
was repeated eight times within one hour.
Western blot analysis for oxidative stress in kidney
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). The procedure of 2,4-
dinitrophenylhydrazine (DNPH) derivatization was car-
ried out on 6 μg of protein for 15 minutes according to
the manufacturer’s instructions. One-dimensional elec-
trophoresis was carried out on 12% SDS/polyacrylamide
gel after DNPH derivatization. Proteins were transferred
to nitrocellulose membranes which were then incubated
in the primary antibody solution (anti-DNP 1: 150) for
two hours, followed by incubation with second antibody
solution (1:300) for one hour at room temperature. The
washing procedure was repeated eight times within
40 minutes.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences) which
was then exposed to Biomax L film (Kodak). For quanti-
fication, ECL signals were digitized using Labwork soft-
ware (UVP). For oxyblot protein analysis, a standard
control was loaded on each gel.
Protocol for RNA extraction
Lysis/binding buffer (High Pure RNA Tissue Kit, Roche,
Germany) 400 μL and an appropriate amount of frozen
kidney was added to a nuclease-free 1.5 mL microcentri-
fuge tube, followed by disruption and homogenization of
the tissue by using a rotor-stator homogenizer (Roche).
The lysate in the microcentrifuge tube was then centri-
fuged for two minutes at 13,000 g. Only the superficially
collected supernatant was utilized for subsequent steps.
Absolute ethanol 200 μL was added to the lysate super-
natant and mixed well. The entire sample in the upper
reservoir was pipetted into a High Pure Filter Tube
(Roche) that was placed in the Collection Tube (Roche).
This sample was then centrifuged for 30 seconds at13,000 g in a standard tabletop microcentrifuge. After
that, the Filter Tube was removed from the Collection
Tube and the flowthrough liquid was discarded. For
each isolation, 90 μL DNase incubation buffer was
pipetted into a sterile 1.5 mL reaction tube, 10 μL
DNase I working solution was then added, mixed and
incubated for 15 minutes at 25 °C. Wash buffer I 500 μL
was then added to the upper reservoir of the filter tube,
which was then centrifuged for 15 seconds at 8,000 g.
The filter tube was removed from the Collection Tube
and the flowthrough liquid was then discarded. Wash
Buffer II 500 μL was added to the upper reservoir of the
Filter Tube, which was then centrifuged for 15 seconds
at 8,000 g and the flowthrough was discarded. Wash buf-
fer II 300 μL was added to the upper reservoir of the fil-
ter tube, which was centrifuged for 2 minutes full-speed
at approximately 13,000 g. The column was then care-
fully removed from the collection tube such that the col-
umn did not contact the flowthrough to avoid ethanol
carryover. The filter tube was then inserted into a
1.5 mL nuclease-free and sterilized microcentrifuge tube.
Elution Buffer 100 μL was added to the upper reservoir
of the filter tube; the tube assembly was then centrifuged
for 1 minute at 8,000 g resulting in eluted RNA in the
microcentrifuge tube.
Reverse transcription qPCR analysis
Quantitative reverse transcription-polymerase chain re-
action (RT-qPCR) was conducted using LightCycler Taq-
Man Master (Roche, Germany) in a single capillary tube
according to the manufacturer’s guidelines for individual
component concentrations as we previously reported
[37,38]. Forward and reverse primers were each designed
based on individual exons of the target gene sequence to
avoid amplifying genomic DNA.
During PCR, the probe was hybridized to its comple-
mentary single-strand DNA sequence within the PCR
target. As amplification occurred, the probe was
degraded due to the exonuclease activity of Taq DNA
polymerase, thereby separating the quencher from re-
porter dye during extension. During the entire amplifica-
tion cycle, light emission increased exponentially. A
positive result was determined by identifying the thresh-
old cycle value at which reporter dye emission appeared
above background.
Statistical analysis
Quantitative data are expressed as means ± SD. Statis-
tical analysis was adequately performed by ANOVA fol-
lowed by Bonferroni multiple-comparison post hoc test.
Statistical analysis was performed using SAS statistical
software for Windows version 8.2 (SAS institute, Cary,
NC). A probability value <0.05 was considered statisti-
cally significant.
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Serial changes of serum levels of creatinine and blood
urea nitrogen and the ratio of urine protein to creatinine
at the end of study period
The serum levels of BUN and creatinine did not differ
among the five groups of animals at the beginning
and within the first two months of the study period
(Figure 1A and C) (p> 0.5). Additionally, the BUN and
creatinine levels did not differ between group 1 (normal
control) and group 2 (NP only) at the end of the study
period (i.e. 24 weeks) (Figure 1B and D) (p> 0.1). How-
ever, the BUN and creatinine levels were notably
increased in group 3 (AD only) at end of 16 weeks and
further increased at the end of the study period as
compared with groups 1 and 2 (all p< 0.01). Further-
more, the BUN and creatinine levels were notablyFigure 1 Serial changes of serum levels of creatinine and blood urea
study period. Serial changes in serum levels of blood urine nitrogen (BUN
induced chronic kidney disease (CKD). B) By 24-week, remarkably increased
normal (group 1) and Nonylphenol (NP)-treated (group 2) rats. Markedly in
groups, but significantly reduced in adenine+NP-treated rats receiving ros
creatinine levels compared to those of BUN by 24-week after CKD inductio
other groups, p< 0.0001 (at 24 week). For A & C): } indicated AD+NP gro
of urine protein to creatinine): * vs. other groups with different symbols (†,
by Scheffe multiple-comparison post hoc test) (n = 10 in each group).increased in group 4 (AD+NP) at the 16 week (all p
< 0.005) and more substantially increased at the end of
the study period compared with those animals in
groups 1, 2 and 3 (Figure 1A and C) (p< 0.0001). Con-
versely, these two parameters were markedly suppressed
in group 5 (AD+NP+ rosuvastatin) when compared
with group 4 in the end of study period (all p< 0.001).
Additionally, the BUN level showed no difference be-
tween groups 3 and 5 (p> 0.1), whereas the creatinine
level was notably lower in group 5 than in group 3 at
the end of study period (p< 0.01). Furthermore, these
two parameters were remarkably higher in group 5 than
in groups 1 and 2 at the end of study period (Figure 1B
and D) (all p< 0.01).
The ratio of urine level of protein to creatinine did not
differ between groups 1 and 5. However, the ratio wasnitrogen and the ratio of urine protein to creatinine at the end of
) (A) and creatinine (C) in different groups of rats after adenine-
serum levels of BUN in adenine (AD)-treated (group 3) rats than in
creased BUN levels in adenine+NP-treated (group 4) rats than in other
uvastatin (Rosu) (group 5) than in group 4. D) Similar changes in serum
n. Statistical analysis by one-way ANOVA. For BUN and creatinine: * vs.
up vs. other groups (at 16, 20 and 24 weeks), p< 0.01. For E) (the ratio
{, }), p< 0.0001. Symbols (*, †, {, }) indicate significance (at 0.05 level
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groups 1 and 5, notably higher in groups 3 and 4 than
that in 2 group, and significantly higher in group 4 than
that in group 3, but it showed no difference between
groups 1 and 5 (Figure 1E).Figure 2 Histological scores of kidney by 24-week after CKD inductio
groups 1 to 5 animals (A to K) showing notably higher degree of loss of b
asterisk), tubular dilatation (blue arrows), tubular necrosis (green arrows), an
enhanced damage in group 4 compared with that in groups 1 and 2, but
crystal formations (green asterisk) in groups 3 and 4 animals. F) * vs. other
significance (at 0.05 level by Bonferroni multiple comparison post hoc test)
50 μm in A-E and 20 μm in G-K.Histopathological scoring of the kidneys
To evaluate the effect of rosuvastatin on NP+AD-
induced renal injury, histological scoring based on the
typical microscopic features of chronic tubular damage,
including extensive tubular necrosis and dilatation, asn. H & E staining [200 x (A to E) & 400x (G to K)] of kidney sections in
rush border in renal tubules (yellow arrowheads), cast formation (blue
d less intact of renal tubule (yellow arrows) in group 3. Further
notably improved in group 5 after rosuvastatin treatment. Also note
groups, p< 0.0001 (by one-way ANOVA). Symbols (*, †, {, }, }) indicate
(n = 10 in each group). Scale bars in right lower corner represent
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adopted (Figure 2). The injury was found to be more se-
vere in group 4 than in groups 1 to 3, notably more se-
vere in group 3 than in groups 1 and 2, but the degree
of injury was less remarkable in group 5 compared with
groups 3 and 4, suggesting that rosuvastatin therapy sig-
nificantly protected the kidney from AD or NP+AD
damage (Figure 2).
Besides, to determine whether rosuvastatin therapy
protected the integrity of renal-tubular architecture from
NP+AD damage, PAS staining for identification of renal
tubular brush border was performed(Figure 3). As
expected, the number of intact renal-tubular brush
border was notably higher in group 5 than in groups 3
and 4, suggesting that rosuvastatin therapy significantly
improved the integrity of renal-tubular architecture from
AD or NP+AD injury (Figure 3).
Protein expressions of inflammatory, ROS, oxidative-stress
biomarkers, and anti-oxidative mediators in renal
parenchymal tissues
The protein expressions of NADPH oxidase (NOX)-1
(Figure 4A) and NOX-2 (Figure 4B), indicators of ROSFigure 3 Percentage of intact renal tubules in CKD rats. Periodic Acid
(A, B, C, D, E) showing notable renal tubular destruction (yellow arrows) in
alleviation in renal tubular damage in group 5 compared to groups 3 and
dilated Bowman's capsules (black asterisks) and fibrotic changes in interstit
other groups by 24-week after CKD induction. L) * vs. other groups, p< 0.0
(at 0.05 level by Bonferroni multiple comparison post hoc test). Scale bars igeneration, were notably higher in groups 2 and 3 than in
group 1, and more markedly increased in group 4 than in
groups 1 to 3, but remarkably reduced in group 5 as com-
pared with group 4 at the end of the study period. Add-
itionally, the protein expressions of NF-κB (Figure 4C), an
indicator of inflammation, was notably higher in group 3
than in groups 1 and 2, more remarkably higher in group
4 compared with those in groups 1 to 3, but it showed sig-
nificantly reduced in group 5 as compared with group 4.
Moreover, the protein expression of ICAM-1 (Figure 4D),
another indicator of inflammatory biomarker, was signifi-
cantly enhanced in groups 2 and 3 than in group 1, further
enhanced in group 4 than in group in groups 1, 2 and 3,
but this parameter was notably reduced in group 5 than in
group 4 at the end of the study period. Furthermore, the
protein expression of oxidative stress, i.e. protein carbo-
nyls (Figure 5A), was increased several folds in groups 2
and 3 as compared with group 1 and further increased
in group 4 than in groups 1 to 3, but it was remarkably
lower in group 5 than in groups 2 to 4. These findings
suggest that AD-NP-induced CKD is through inflamma-
tion and ROS generation that could be suppressed by
rosuvastatin therapy.Schiff (PAS) staining (200 x) of kidney sections in groups 1 to 5 animals
groups 3 and 4 compared with groups 1 and 2. Remarkable
4. Also note the thickened basal membrane (green arrowheads) and
ial areas of kidney (blue asterisks) in groups 3 and 4 compared with
001 (by one-way ANOVA). Symbols (*, †, {, }) indicate significance
n right lower corner represent 50 μm in A to E (n = 10 in each group).
Figure 4 Changes in protein expressions of inflammatory markers in kidney 24 weeks after CKD induction A & B). Remarkably increased
protein expressions of NADPH oxidase (NOX)-1 and NOX-2 in groups 2 and 3 than in group 1. Notably higher expressions in group 4 than in
groups 1, 2, and 3, but significantly decreased in group 5 compared with group 4. For NOX-1 and NOX-2, *p< 0.001 between indicated
groups. C) Notably elevated protein expression of nuclear factor (NF)-κB in group 3 than in groups 1 and 2. Further increase in group 4
compared with in groups 1, 2, and 3, but significantly lower in group 5 than in group 4. *p< 0.002 between indicated groups. D) Significantly higher
protein expression of inter-cellular adhesion molecule (ICAM)-1 in groups 2 and 3 than in group 1. Further remarkable increase in group 4 compared
with groups 1, 2, and 3, but notably lower in group 5 than in group 4. *p< 0.001 between indicated groups. All statistical analyses using one-
way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, {, }) indicate significance (at 0.05 level) (n = 10 in
each group).
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and NQO1 (Figure 5D), two anti-oxidative biomarkers,
were remarkably higher in groups 3 and 4 than in
groups 1 and 2 and further higher in group 5 than in
groups 3 and 4. These findings suggest that anti-
oxidant generation was elicited in response to AD-
and AD-NP-induced CKD and this protective mechan-
ism was further up-regulated by rosuvastatin therapy
in this setting of CKD.
The mRNA and protein expressions of apoptotic and anti-
apoptotic biomarkers
The protein expressions of caspase 3 (Figure 6A) and
Bax (Figure 6B), two apoptotic biomarkers, were notablyincreased in groups 2 and 3 than in group 1, remarkably
elevated in group 4 compared with groups 1 to 3, but
they showed marked reductions in group 5 compared to
group 4. Conversely, the protein expression of Bcl-2
(Figure 6C), an index of anti-apoptosis, was notably
reduced in groups 2 and 3 compared with group 1, more
markedly reduced in group 4 than in groups 2 and 3.
However, it was significantly increased in group 5 com-
pared to groups 2, 3, and 4.
Similarly, the mRNA expressions of caspase 3
(Figure 6D) and Bax (Figure 6E) were notably higher in
group 2 than in group 1, further higher in groups 3 and
4 than in groups 1 and 2, but they were markedly lower
in group 5 than in groups 3 and 4. In contrast, the
Figure 5 Changes in protein expressions of oxidative stress and anti-oxidant markers in kidney at 24-week after CKD induction A & B).
Significantly increased oxidized protein expression in groups 2 and 3. Further increase in group 4 compared to groups 1, 2 and 3, but remarkably
reduced in group 5 compared with group 4. * vs. other groups, p< 0.001. C) Notably increased protein expression of heme oxygenase (HO)-1 in
groups 3 and 4 compared with that in groups 1 and 2. Significantly increased expression in group 2 than in group 1, and highest in group 5
compared with that in other groups. * vs. other groups, p< 0.0001. D) Notably higher protein expression of NAD(P)H quinone oxidoreductase
(NQO) 1 in groups 3 and 4 than in groups 1 and 2, and highest in groups 5 compared with that in other groups. * vs. other groups, p< 0.0001.
All statistical analyses using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, {, }, }) indicate
significance (at 0.05 level). (n = 10 in each group).
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lower in groups 2 to 4 than in group 1, but it was signifi-
cantly higher in group 5 than in groups 2 to 4. These
findings suggest that the apoptotic signaling pathway,
which is also involved in AD-NP-induced CKD, could be
reversed by rosuvastatin therapy.
Changes in mRNA expression of vasoactive, inflammatory,
and anti-oxidative mediators in renal parenchyma after
CKD induction
The mRNA expression of endothelin (ET)-1 (Figure 7A),
an index of endothelial damage/vasoconstriction, was
notably higher in group 3 than in groups 1 and 2, further
markedly higher in group 4 than in groups 1 to 3. How-
ever, it was remarkably lower in group 5 than in group4. The mRNA expressions of tumor necrosis factor
(TNF)-α (Figure 7B) and matrix metalloproteinase
(MMP)-9 (Figure 7C), two indicators of inflammation,
were remarkably higher in group 3 than in groups 1 and
2, further higher in group 4 than in groups 1 to 3, but
they were notably reduced in group 5 compared to
group 4. On the other hand, the mRNA expressions of
endothelial nitric oxide synthase (eNOS) (Figure 7D) an
anti-inflammatory index, was notably lower in groups 2
and 3 than in group 1, and significantly reduced in
group 4 compared with group 1. However, this bio-
marker was substantially increased in group 5 compared
with groups 2 to 4. The mRNA expression of interleukin
(IL)-10 (Figure 7E), another anti-inflammatory index,
was significantly increased in group 4 than in groups 1
Figure 6 The protein and mRNA expressions of apoptotic and anti-apoptotic biomarkers in kidney at 24-week after CKD induction A).
Significantly higher protein expression of caspase 3 in groups 2 and 3 than in group 1. Further increase in group 4 than in groups 1, 2, and 3,
but drastically reduced in group 5 compared with that in group 4. * vs. other groups, p< 0.0001. B) Significantly elevated protein expression of
Bax in group 2 than in group 1. Further increase in group 3 than in group 2, and highest in group 4. Notable reduction in group 5 than in
group 4. * vs. other groups, p< 0.0001. C) Remarkably suppressed protein expression of Bcl-2 in group 4 than in groups 2 and 3. Markedly
reduced expression in groups 2, 3, and 4 than in groups 1 and 5. Note significant reduction in group 5 compared with group 1. * vs. other
groups, p< 0.0001. D) Significantly higher mRNA expression of caspase 3 in group 2 than in group 1. Notably increased expression in groups 3
and 4 than in group 2, but significantly reduced in group 5 compared with groups 3 and 4. * vs. other groups, p< 0.001. E) Markedly increased
mRNA expression of Bax in group 2 than in group 1, further increased in groups 3 and 4 than in groups 1 and 2, but significantly reduced in
group 5 than in groups 2 to 4. * vs. other groups, p< 0.0001. F) Remarkably lower mRNA expression of Bcl-2 in groups 3 and 4 than in group
2, and notably lower in group 2 than in groups 1 and 5. Significantly lower expression in group 5 than in group 1. * vs. other groups, p< 0.001.
All statistical analyses using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, {, }) indicate significance
(at 0.05 level) (n = 10 in each group).
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compared with groups 1 to 4. Additionally, the mRNA
expressions of HO-1 (Figure 7F), NQO1 (Figure 7G),
glutathione reductase (GR) (Figure 7H), and glutathione
peroxidase (GPx) (Figure 7I), four anti-oxidative indica-
tors, were significantly higher in group 4 than in groups
1 to 3, and more markedly increased in group 5 than in
group 4. These findings suggest that anti-inflammatory
and anti-oxidative responses after induction of CKD
with AD & NP and enhancement of these responses fol-
lowing rosuvastatin therapy.Findings from IF and IHC staining
The IF staining for CD68-positive cell (Figure 8), a
surface marker of macrophage in kidney tissue, was
found to be remarkably increased in groups 3 and 4
than in groups 1 and 2, but it showed notably reducedin group 5 than in groups 3 and 4. These findings sug-
gest that rosuvastatin treatment offered an anti-
inflammatory effect.
The IHC staining (Figure 9) revealed that the expression
of GR, an anti-oxidative enzyme, was remarkably higher in
group 4 than in groups 1 to 3, and highest in group 5.
These findings, together with results from RT-PCR
(Figure 7H), further suggest that anti-oxidative re-
sponse was elicited by rosuvastatin treatment contribu-
ted to anti-oxidative effects after AD & NP-induced
CKD in this study.
Discussion
This study, which used a rodent model to investigate the
therapeutic impact of rosuvastatin therapy on AD-NP-
induced CKD, provided several striking implications.
First, the major contributors to AD-NP-induced CKD
were found to be inflammatory reaction, ROS generation,
Figure 7 Changes in mRNA expressions in kidney at 24-week after CKD induction A). Significantly higher endothelin (ET)-1 expression in
groups 2 and 3 than in group 1. Further increase in group 4 compared with groups 1 to 3, but significantly lower in group 5 than in group 4.
B) Notably elevated tumor necrosis factor (TNF)-α expression in group 2 than in group 1, higher in group 3 than in groups 1 and 2, and highest
in group 4. C) Significantly increased matrix metalloproteinase (MMP)-9 expression in groups 2 and 3 than in group 1, and highest in group 4.
D) Remarkably lower endothelial nitric oxide synthase (eNOS) expression in groups 2, 3, and 4 than in group 1, and highest in group 5. E) Significantly
higher interleukin (IL)-10 expression in group 4 than in groups 1 and 2, and highest in group 5. F) Significantly higher HO-1 expression in group 3 than
in groups 1 and 2, further increased in group 4 compared with groups 1 to 3, and highest in group 5. G & H) Notably increased expressions of NQO 1
and glutathione reductase (GR) in group 4 than in groups 1 to 3, and highest in group 5. I) Significantly increased glutathione peroxidase (GPx)
expression in group 3 than in groups 1 and 2, further increased in group 4 than in groups 1 to 3, and highest in group 5. All statistical analyses using
by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, {, }, }) indicate significance (at 0.05 level) (n= 10 in each
group).
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nificantly preserved architectural integrity of renal paren-
chyma and attenuated the deterioration of renal function
after AD-NP-induced kidney damage. Third, rosuvastatin
therapy consistently initiated anti-inflammatory, anti-
apoptotic, and anti-oxidative effects.
Aggravation of AD-Induced renal dysfunction by NP
Although AD-induced CKD animal model has been vali-
dated in previous studies [27-29], the authors of those
studies used a relatively higher dose of AD (i.e. 0.75%)
compared with that used in the present study (i.e.
0.25%). Our results, therefore, demonstrated that AD
successfully induced CKD in a rodent model even at
one-third of the reported dose. Furthermore, the novel
finding of the current study is that NP feeding aggra-
vated the deterioration of AD-induced renal function
impairment. This finding implicates that not only is NP
an endocrine-disrupting organic compound in theenvironment [25], but it also participates in deteriorating
the mammalian renal function in subjects with pre-
existing chronic renal disease.
One important finding in the present study is that both
gross anatomical and histological findings showed irregu-
lar appearance and crystal depositions in kidneys after AD
treatment. Consistently, previous studies [27-29] have also
shown similar findings. Besides, another finding of interest
in the current study is that despite the lack of significant
difference in renal functions (i.e. serum BUN and creatin-
ine levels) between the normal controls and NP-fed ani-
mals by the end of study period, immense differences in
renal parenchyma including the histological pictures,
mRNA, and protein expressions of various inflammation-
and apoptosis-related molecules were noted between the
two groups. Our findings, therefore, may suggest that NP,
an environmental organic compound [25], may play an es-
sential role in aggravating mammalian CKD on chronic
exposure.
Figure 8 Immunofluorescent (IF) staining for renal expressions of inflammatory markers at 24-week after CKD induction A to E).
Identification of macrophage (CD68+ cells) (red arrows) accumulation in kidney parenchyma of each group of rats using IF staining, showing
significantly higher number of macrophage in group 2 than in group 1. Further increase noted in group 3 than in groups 1 and 2, and
substantially higher in group 4 than in groups 1 to 3, but markedly lower in group 5 compared with groups 3 and 4. F) * vs. other groups,
p< 0.0001. Nuclei (blue color) stained with 4’,6-diamidino-2-phenylindole (DAPI) as counter staining. All pictures taken under high-power field
(HPF) 400x. Scale bars in right lower corner represent 50 μm. All statistical analyses using one-way ANOVA, followed by Bonferroni multiple
comparison post hoc test. Symbols (*, †, {, }, }) indicate significance (at 0.05 level) (n = 10).
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Interestingly, although AD-induced CKD in rodents is a
well-established model [27-29], the mechanistic basis of
AD-induced CKD has seldom been investigated [27-29].
Additionally, the mechanism of AD-NP-induced CKD in
the rat model has not been reported. Another important
finding in the present study is that the expressions of in-
flammatory markers including CD68-positive cells, TNF-
1α, MMP-9, ICAM-1, and NF-κB were notably higher in
NP-treated animals (group 2), and further increased in
the AD-treated group (group 3), and highest in the AD-
NP-treated group (group 4) compared with those in the
normal controls (group 1). The principal findings of the
present study are that ROS production (NOX-1, NOX-2),
oxidized protein expression (protein carbonyls), and endo-
thelial damage index (ET-1 gene expression) were notably
increased in group 2, further increased in group 3, and
substantially elevated in group 4 compared with group 1.
Numerous previous studies have shown that CKD elicits
rigorous inflammatory reaction, oxidative stress, and the
generation of ROS [1,18,19,30-33], which, in turn, cause
further damage to renal parenchyma and destroy the
architectural integrity of the kidney. In this way, ourfindings, in addition to reinforcing those of previous stud-
ies [1,18,19,30-33], further showed that AD, NP, and com-
bined AD-NP treatment caused different degrees of renal
damage in a rodent model of CKD.
Of importance is that, as compared with group 4 ani-
mals, the expressions of these inflammatory and oxida-
tive biomarkers at both gene and protein levels were
significantly suppressed in group 5 animals following
rosuvastatin administration. Moreover, the generations
of anti-oxidants at IHC stain (GR-positive cells), protein
(HO-1 and NQO1) and mRNA (HO-1, NQO1, GR, and
GPx) levels were also markedly enhanced in group 5 ani-
mals compared with those in group 4. Besides, at both
protein and mRNA levels, the apoptotic biomarkers
(caspase 3 and Bax) were markedly reduced, whereas the
anti-apoptotic biomarker (Bcl-2) and anti-inflammatory
biomarkers at gene level (IL-10, eNOS) were signifi-
cantly enhanced in group 5 animals compared with
those in group 4. These results, at least in part, may sug-
gest the involvement of the apoptotic signaling pathway
in CKD. Our findings further support those of previous
studies showing that cellular apoptosis/death is always
present in CKD [39,40].
Figure 9 Immunohistochemical (IHC) staining for renal expressions of anti-oxidant markers at 24-week after CKD induction A to E).
Identification of GR-positive cells accumulation in kidney parenchyma of each group using IHC staining (200x). Note remarkably increased
expression in group 4 than in groups 1 to 3, and highest in group 5. Scale bars in right lower corner represent 50 μm. (n = 10).
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distinctive properties of being anti-inflammatory [33],
inhibiting ROS production [41,42] and reducing oxi-
dant/free radical generations [43,44]. Using an animal
model of AD-NP-induced CKD, the results of the
present study also revealed that rosuvastatin also pos-
sesses all of the above-mentioned distinctive properties
[33,41-43]. Our findings, therefore, in addition to cor-
roborating those of previous studies [33,41-44], suggest
the potential benefit of early statin use in the setting
of CKD.
Study limitations
This study, however, has its limitations. First, although
multifaceted signaling pathways were found to be
involved in this AD-NP-induced CKD animal model,
we remain uncertain how many signaling pathways
exactly contribute to our observations. Second, the
results of this study did not specify the most important
mechanism involved in AD-NP-induced CKD. Third,
we remain uncertain for why a bit different association
between antioxidants and detoxifying enzymes and
oxidative-stress biomarkers were found in the current
study. Interestingly, a similar result has also been found
recently in a rat animal model of acute kidney
ischemia-reperfusion injury with stem cell therapy [36].
We suggest that the findings in the current study may
implicate that inherent anti-oxidant system can beinitiated by CKD in response to NP, AD, and AD+NP
stress and that this effect could be further enhanced by
rosuvastatin therapy.
Conclusions
The present study revealed that chronic NP treatment
aggravated AD-induced CKD in a rodent model. The
underlying mechanisms include augmentation of inflam-
matory reaction, generation of ROS, and enhancement
of cellular apoptosis which were found to be suppressed
by rosuvastatin therapy.
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